Focus Partners Wealth Has $3.48 Million Stake in Sanofi (NASDAQ:SNY)

Focus Partners Wealth lifted its holdings in Sanofi (NASDAQ:SNY) by 8.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 71,808 shares of the company’s stock after purchasing an additional 5,795 shares during the quarter. Focus Partners Wealth’s holdings in Sanofi were worth $3,483,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Arkadios Wealth Advisors grew its holdings in Sanofi by 19.0% during the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock worth $227,000 after purchasing an additional 751 shares during the period. Kentucky Trust Co bought a new stake in Sanofi in the 4th quarter valued at about $436,000. Park Avenue Securities LLC increased its stake in Sanofi by 14.3% during the 4th quarter. Park Avenue Securities LLC now owns 68,982 shares of the company’s stock worth $3,327,000 after acquiring an additional 8,615 shares during the period. Van ECK Associates Corp raised its stake in Sanofi by 18.1% in the fourth quarter. Van ECK Associates Corp now owns 662,762 shares of the company’s stock valued at $31,965,000 after purchasing an additional 101,726 shares in the last quarter. Finally, Sound Income Strategies LLC boosted its position in shares of Sanofi by 156,520.9% during the 4th quarter. Sound Income Strategies LLC now owns 67,347 shares of the company’s stock worth $3,248,000 after acquiring an additional 67,304 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Stock Up 3.4%

Sanofi stock opened at $50.86 on Friday. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $128.49 billion, a price-to-earnings ratio of 20.43, a P/E/G ratio of 1.01 and a beta of 0.55. The firm has a 50 day simple moving average of $53.50 and a 200 day simple moving average of $51.92.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.04. The company had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The firm’s revenue was down 11.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.78 EPS. On average, analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be issued a dividend of $2.0369 per share. The ex-dividend date is Friday, May 9th. This is a boost from Sanofi’s previous annual dividend of $1.48. This represents a yield of 3.1%. Sanofi’s dividend payout ratio is currently 57.14%.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. BNP Paribas assumed coverage on shares of Sanofi in a report on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 target price for the company. The Goldman Sachs Group started coverage on shares of Sanofi in a research report on Friday, March 21st. They set a “neutral” rating and a $65.00 price objective for the company. Hsbc Global Res raised shares of Sanofi to a “strong-buy” rating in a research note on Monday, April 28th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $63.33.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.